Boston Scientific Corp (BSX) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Boston Scientific Corp (BSX)

48.55

-0.30 (0.61%)

as of Jun 5, 2026, 8:00:00 pm Market Open.

100 watching

Investor Insights

Jun 5, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Boston Scientific Corp (BSX) has garnered mixed reviews from experts, reflecting a range of perspectives on its investment potential. While it is recognized as a leader in the medical device industry with products in cardiology and endoscopy, analysts caution that the stock has faced significant challenges over the past year, including slowing organic growth and increased competition from rivals like Medtronic, Abbott, and Johnson & Johnson. The recent market performance has led to concerns about its high valuation, with some experts recommending a wait-and-see approach rather than aggressive investment. Others, however, argue that despite the near-term weakness, the company is well-managed and poised for long-term growth, driven by an aging population and demand for less invasive devices. Overall, while the stock appears attractive at the current price, caution is advised given the current market dynamics and valuation metrics.

Consensus

Mixed

Valuation

Overvalued

Similar

Medtronic,MDT

DON'T BUY

It is at a new high in terms of price but not new highs in terms of Price/Book. There is no yield and a 25% downside risk.

BUY

It is a leader in the field so the price is at a premium for a good reason. Has had a good bounce. You could also look at MedTech and Thermo-Fisher.

TOP PICK

World's leader in med tech. He's doubling down on US healthcare. Leader in cardio surgical technology. Healthcare, neglected through Covid, will be a very high growth area for the next couple of years. No dividend. (Analysts’ price target is $49.96)

PARTIAL SELL

Can be a safe haven stock. Health care offers defence. But BSX has had a big run and he expects this market to roll over a bit. Take some profits and wait for opportunities, which could mean buying this back in 2-3 months. Has fantastic fundamentals, but valuation is rich.

BUY

Likes it very much. Higher growth. Under pressure post-earnings. Predominantly everything cardiovascular. Covid put off elective surgeries, and these are starting to return. For the rest of 2022, increased volume might offset inflationary pressures.

WAIT

She has owned it for many years and it has not done anything. The COVID scares cast shadows over medical procedure demand. As a medical device provider it has faced head winds. Demand should ramp back up, but it will take confidence by patients to return for procedures.

PAST TOP PICK

(A Top Pick Dec 01/20, Up 22%) Covid delayed surgeries. Labour shortages. Both are holding the stock back, but will improve. Solid, long-term core investment.

HOLD

Holds other healthcare plays. There is a good place for these names in portfolios. The organic growth from resuming treatment and surgeries will be interesting to follow. Wouldn't worry about the pullback.

WAIT

BSX vs. MDT Two great companies. In the implantable medical device business. Loves the area. Too expensive, as investors have flocked to them and the multiple has increased. Would love to own both if prices came down substantially.

BUY

Medical device maker. It has been a bit of a laggard. It was the market darling until 2019 and then they started to have a couple of misses and issues with products. He thinks these are all transient issues. He thinks in 2022 they will grow revenue in high single digits. He is going to stick with it and would buy it here.

PAST TOP PICK

(A Top Pick Dec 01/20, Up 33%) He would buy it again. They had a decade of no-growth. In the last 3-5 years they introduced successful products that got their revenue going again. A lot of their procedures are not necessary today but will be over the next few months. The volumes are coming back. It is at the cheaper end of a lot of healthcare stocks.

BUY ON WEAKNESS

It's one of Abbott's biggest competitors. It's in an attractive industry, medical equipment, where companies earn good returns. But BSX's valuation is high, gotten ahead of itself (like the whole sector), so wait for a pullback. BSX had a strong quarter as non-elective surgeries have bounced back, but its PE is rich.

PAST TOP PICK

(A Top Pick Jul 14/20, Up 23%) It had a couple of disappointing news items involving a couple of their products. They are playing catch-up on elective surgeries. It is one he really likes and continues to hold.

TOP PICK

It is a medical device company and people are starting to be able to get in to see their doctor and take care of things. A lot of their revenues are tied to non-deferrable procedures. That is positive for the whole group and they have company-specific catalysts also. (Analysts’ price target is $49.00)

HOLD

Looking at the longer term chart, they had a dip around the time China announced first cases of covid. Underperformed relative to others, like other mid-tech companies. Lots of procedures were delayed in hospitals. Now there will be catch up for this. At these levels, there is still some room to run. Could go to $48 range.

Showing 16 to 30 of 69 entries

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)